Top 20 of Melanoma, Experimental

Article title # Publications/# Citations

Inhibitory Fc receptors modulate in vivo cytotoxicity against tumor targets.

2000: RAClynes; LGPresta; JVRavetch; TLTowers;

371

Vaccination with irradiated tumor cells engineered to secrete murine granulocyte-macrophage colony-stimulating factor stimulates potent, specific, and long-lasting anti-tumor immunity.

1993: KBrose; GDranoff; PGolumbek; HHamada; VJackson; EJaffee; ALazenby; HLevitsky; RCMulligan; DPardoll;

329

Requirement for Valpha14 NKT cells in IL-12-mediated rejection of tumors.

1997: JCui; YKaneko; MKanno; TKawano; EKondo; HKoseki; HSato; TShin; MTaniguchi; IToura;

269

Tumor regression and autoimmunity after reversal of a functionally tolerant state of self-reactive CD8+ T cells.

2003: PAAntony; LAde Jong; TADellemijn; LFeigenbaum; SEFinkelstein; DMHeimann; LNHwang; CAKlebanoff; ... AMKruisbeek; WWOverwijk; DCPalmer; NPRestifo; SARosenberg; PJSpiess; DRSurman; MRTheoret; FAVyth-Dreese; ZYu;

247

Induction of tumor immunity by removing CD25+CD4+ T cells: a common basis between tumor immunity and autoimmunity.

1999: SSakaguchi; JShimizu; SYamazaki;

232

Localization of matrix metalloproteinase MMP-2 to the surface of invasive cells by interaction with integrin alpha v beta 3.

1996: RTAimes; PCBrooks; DACheresh; JPQuigley; LCSanders; WGStetler-Stevenson; SStrömblad; TLvon Schalscha;

224

VEGF-Trap: a VEGF blocker with potent antitumor effects.

2002: KBailey; PBoland; EBurova; SDCroll; TDaly; SDavis; JPFandl; LHo; ... JHolash; THuang; DHylton; EIoffe; RLeidich; NPapadopoulos; CRadziejewski; JSRudge; MRussell; SJWiegand; GDYancopoulos;

193

CD8+ T cell immunity against a tumor/self-antigen is augmented by CD4+ T helper cells and hindered by naturally occurring T regulatory cells.

2005: AAkpinarli; PAAntony; CCChan; SEFinkelstein; CAKlebanoff; WWOverwijk; DCPalmer; CAPiccirillo; ... NPRestifo; SARosenberg; PJSpeiss; DRSurman;

184

Acquisition of full effector function in vitro paradoxically impairs the in vivo antitumor efficacy of adoptively transferred CD8+ T cells.

2005: SEFinkelstein; LGattinoni; KKerstann; CAKlebanoff; DCPalmer; NPRestifo; SARosenberg; MRTheoret; CWrzesinski; ZYu;

178

Regulation of the innate and adaptive immune responses by Stat-3 signaling in tumor cells.

2003: RBhattacharya; LBurdelya; DCoppola; WDalton; DGabrilovich; RHeller; RJove; MKortylewski; ... GNiu; DPardoll; KShain; TWang; HYu; SZhang;

174

Signals leading to apoptosis-dependent inhibition of neovascularization by thrombospondin-1.

2000: NBouck; SECrawford; MFebbraio; BJimenez; RLSilverstein; OVVolpert;

174

Synergism of cytotoxic T lymphocyte-associated antigen 4 blockade and depletion of CD25(+) regulatory T cells in antitumor therapy reveals alternative pathways for suppression of autoreactive cytotoxic T lymphocyte responses.

2001: JPAllison; CJMelief; ROffringa; TNSchumacher; RPSutmuller; REToes; LMvan Duivenvoorde; Avan Elsas; MEWildenberg;

172

Tumor response to radiotherapy regulated by endothelial cell apoptosis.

2003: CCordon-Cardo; ZFuks; MGarcía-Barros; AHaimovitz-Friedman; RKolesnick; DLyden; FParis; SRafii;

165

The central role of CD4(+) T cells in the antitumor immune response.

1998: RHayashi; KHung; ALafond-Walker; HLevitsky; CLöwenstein; DPardoll;

164

Combination immunotherapy of B16 melanoma using anti-cytotoxic T lymphocyte-associated antigen 4 (CTLA-4) and granulocyte/macrophage colony-stimulating factor (GM-CSF)-producing vaccines induces rejection of subcutaneous and metastatic tumors accompanied by autoimmune depigmentation.

1999: JPAllison; AAHurwitz; Avan Elsas;

155

Antibody mediated in vivo delivery of small interfering RNAs via cell-surface receptors.

2005: DChowdhury; DMDykxhoorn; YFeng; SKussman; SKLee; JLieberman; WAMarasco; DPalliser; ... PShankar; ESong; DBWeiner; PZhu;

154

Role of bone marrow-derived cells in presenting MHC class I-restricted tumor antigens.

1994: MAhmadzadeh; PGolumbek; AYHuang; EJaffee; HLevitsky; DPardoll;

154

Evidence for a novel gene associated with low tumor metastatic potential.

1988: GBevilacqua; LKopper; LALiotta; MESobel; PSSteeg; JETalmadge; UPThorgeirsson;

152

Mesenchymal stem cells: potential precursors for tumor stroma and targeted-delivery vehicles for anticancer agents.

2004: MAndreeff; BNBekele; MCabreira-Hansen; REChamplin; JLDembinski; FCMarini; MStudeny; CZompetta;

152

Antiangiogenic therapy of experimental cancer does not induce acquired drug resistance.

1997: TBoehm; TBrowder; JFolkman; MSO'Reilly;

145